Hong Kong is expanding clinical trials of histotripsy, a non-invasive treatment that uses focused ultrasound to destroy tumours, as the city seeks to establish a role in developing the technology for kidney cancer.The CUHK Medical Centre, Gleneagles Hospital Hong Kong and Hong Kong Sanatorium & Hospital would begin trials involving 30 patients targeting kidney cancer, the Li Ka Shing Foundation said on Wednesday.The trials mark the latest development in Hong Kong business tycoon Li Ka-shing’s...
Next-gen ultrasound cancer treatment advances: does the evidence match commercial hype?
